The effect of zoledronic acid on bone metastasis is mainly to inhibit the activity of osteoclasts in vivo, reduce bone resorption and destruction, thus relieving patients’ symptoms, stopping tumor-induced osteolytic lesions, and preventing fractures and other complications. Bone metastasis malignant tumor late manifestation, can cause bone destruction, resorption, resulting in patients with pain, fractures, increased blood calcium and other complications. Zoledronic acid, as a bisphosphonate drug, can inhibit the activity of osteoclasts in the body and reduce bone resorption and destruction, the main principles are as follows. 1. Inhibit the activity of osteoclasts: Zoledronic acid can inhibit the differentiation and maturation of osteoclasts, and inhibit the aggregation of osteoclasts at the site of bone resorption. 2. Inducing apoptosis of osteoclasts: Zoledronic acid can inhibit protein isoprenylation and induce apoptosis of osteoclasts. 3. Blocking the release of tumor cytokines: Zoledronic acid can block the release of calcium ions induced by some stimulating factors. Zoledronic acid on bone metastases mainly play a symptomatic as well as preventive role, bone metastasis patients are recommended to timely hospital consultation, active treatment of primary disease.